HealthPharma & Biotech
Amryt Pharma PLC

Amryt Pharmaceuticals’ Episalvan could have “significant commercial success”, says boss

Joseph Wiley, chief executive elect of Amryt Pharmaceuticals, tells Proactive Investors the company is focused on treatment for rare orphan diseases.

Its lead product Episalvan, used to accelerate the healing of partial thickness wounds in adult, has already been approved in Europe and Wiley says there is potential for “significant commercial success”.

Amryt is to make its AIM debut by reversing into listed investment firm Fastnet Equity PLC (LON:FAST)  in a deal that values it at £29.6mln.

Quick facts: Amryt Pharma PLC

Price: £1.34

Market: AIM
Market Cap: £67.51 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...



Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO

Amryt Pharma PLC (LON:AMYT) has been granted orphan drug status in the US for  a compound called AP102 to treat patients with the excess growth condition acromegaly. Chief operating officer Rory Nealon tells Proactive: ''Our focus is to acquire, develop and commercialise products in the...

on 11/07/2016


Euronext Growth Dublin Notice

2 days, 20 hours ago

Circular to Shareholders

1 week, 2 days ago

Schedule One

2 weeks, 3 days ago

Schedule One - Amryt Pharma plc

2 weeks, 3 days ago

Suspension of Trading on Euronext

2 weeks, 4 days ago

2 min read